In the latest trading session, 0.52 million Checkpoint Therapeutics Inc (NASDAQ:CKPT) shares changed hands as the company’s beta touched 1.27. With the company’s most recent per share price at $3.99 changing hands around $0.0 or 0.13% at last look, the market valuation stands at $195.08M. CKPT’s current price is a discount, trading about -12.78% off its 52-week high of $4.50. The share price had its 52-week low at $1.38, which suggests the last value was 65.41% up since then. When we look at Checkpoint Therapeutics Inc’s average trading volume, we note the 10-day average is 9.96 million shares, with the 3-month average coming to 2.51 million.
Analysts gave the Checkpoint Therapeutics Inc (CKPT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CKPT as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Checkpoint Therapeutics Inc’s EPS for the current quarter is expected to be 0.
Checkpoint Therapeutics Inc (NASDAQ:CKPT) trade information
Instantly CKPT is in green as seen in intraday trades today. With action -0.13%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 24.84%, with the 5-day performance at -0.13% in the red. However, in the 30-day time frame, Checkpoint Therapeutics Inc (NASDAQ:CKPT) is 20.69% up. Looking at the short shares, we see there were 7.15 million shares sold at short interest cover period of 9.81 days.
Checkpoint Therapeutics Inc (CKPT) estimates and forecasts
Year-over-year growth is forecast to reach -100.00% down from the last financial year.
The company’s revenue for the corresponding quarters a year ago was 6k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 26.32%. The 2025 estimates are for Checkpoint Therapeutics Inc earnings to increase by 72.34%.
Checkpoint Therapeutics Inc (NASDAQ:CKPT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 19.83% of Checkpoint Therapeutics Inc shares while 18.09% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 22.56%.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 1.09 shares estimated at $4.36 million under it, the former controlled 2.27% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 1.52% of the shares, roughly 732.7 shares worth around $2.92 million.
